clinical trial · NCT06254664
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device
COPDTiotropium 18 µg inhalation powder, hard capsuleZephir inhaler
brief summary
An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device. Zephir inhaler robustness will be assessed by in vitro testing of the Zephir inhaler after 12 weeks of patient use
started
Oct 3, 2022
primary completion
Jul 7, 2023
completion
Oct 27, 2023
last updated
Feb 12, 2024
official title
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Zephir Inhaler Device
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol